Relmada Therapeutics, Inc.
RLMD
$0.627
$0.0172.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.81% | 5.88% | 14.13% | -22.28% | 18.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.30% | -38.82% | -7.39% | 5.57% | -13.01% |
| Change in Net Operating Assets | 100.52% | -265.03% | 217.82% | 6.39% | -536.93% |
| Cash from Operations | 64.57% | -105.32% | 47.17% | -25.59% | -1.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -56.52% | 35.38% | -29.72% | 15.19% | 39.33% |
| Cash from Investing | -56.52% | 35.38% | -29.72% | 15.19% | 39.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -92.52% | -- | 100.00% |
| Cash from Financing | -- | -- | -92.52% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.52% | -214.08% | 493.89% | -180.21% | 127.25% |